Over 200 rare and fully penetrant pathogenic mutations in amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1 and PSEN2) cause a subset of early-onset familial Alzheimer's disease (EO-FAD). Of these, 21 cases of EO-FAD families carrying unique APP locus duplications remain the only pathogenic copy number variations (CNVs) identified to date in Alzheimer's disease (AD). Using highdensity DNA microarrays, we performed a comprehensive genome-wide analysis for the presence of rare CNVs in 261 EO-FAD and early/mixed-onset pedigrees. Our analysis revealed 10 novel private CNVs in 10 EO-FAD families overlapping a set of genes that includes: A2BP1, ABAT, CDH2, CRMP1, DMRT1, EPHA5, EPHA6, ERMP1, EVC, EVC2, FLJ35024 and VLDLR. In addition, CNVs encompassing two known frontotemporal dementia genes, CHMP2B and MAPT were found. To our knowledge, this is the first study reporting rare gene-rich CNVs in EO-FAD and early/mixed-onset AD that are likely to underlie pathogenicity in familial AD and perhaps related dementias.
INTRODUCTION
Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder. Family history is the second biggest risk factor in AD following age. 1 The four established AD genes, amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1, PSEN2) and apolipoprotein E (APOE) have been estimated to account for 30-50% of the genetic variance of AD. 2 Attempts to identify additional AD genes have been largely limited to the search for simple DNA sequence variants (mutations and singlenucleotide polymorphisms) that influence AD susceptibility or time-to-onset. 3, 4 Genome-wide association studies have identified several common AD-associated polymorphisms with very small effect sizes. 5 Recent studies estimate that structural variations in the genome, including copy number variations (CNVs) 6 make a significant contribution to genetic and phenotypic variation. 7, 8 CNVs vary in size from a few kilobases (kb) to several megabases (Mb), but in most instances arbitrarily indicate DNA segments that are 41 kb in length. Several recent studies have successfully identified CNVs that underlie pathogenesis of complex diseases such as autism, 9-11 schizophrenia 12, 13 and human immunodeficiency virus. 14, 15 However, the contribution of CNVs to disease risk is highly complex. Information regarding CNV penetrance, frequency and functional implications is still rudimentary. 16, 17, 18 Nonetheless, the influence of large CNVs on phenotype is estimated to be clinically significant 16 and identification of large, rare CNVs predisposing to various diseases has proven to be successful. [19] [20] [21] Based on the above facts, we set out to identify rare pathogenic CNVs in our collection of early-onset familial AD (EO-FAD) cohorts. Specifically, we searched for large (4100 kb), novel (not previously reported in the database of genomic variants (DGV)) CNVs that co-segregate with disease status within pedigrees.
MATERIALS AND METHODS

Family cohorts
Two large family-based AD sample sets were used in this study: The National Institute of Mental Health Alzheimer's Disease Genetics Initiative Study (NIMH) consisting of 1439 individuals from 436 families of which 131 early/mixed-onset families were included here (that is, families with X1 affected individual showing an age of onset o65) and the National Cell Repository for Alzheimer's Disease (NCRAD) consisting of 1108 samples from 331 pedigrees, of which 130 early/mixed-onset AD families were used here. Both AD family cohorts have been previously described. 22 Overall, a total of 1009 subjects from 261 early/mixed-onset families were used in the CNV analysis.
Genotyping and CNV analyses DNA samples from 1009 subjects in the NIMH and NCRAD AD family cohorts were processed on Affymetrix Human Genome-Wide SNP 6.0 arrays (Affymetrix Inc., Santa Clara, CA, USA). A total of 43 samples that failed to pass quality control, including gender validation, array quality and large chromosomal abnormalities were excluded from the study, as described in detail elsewhere. 23, 24 CNVs 4100 kb were inferred from probe intensity data using PennCNV 25 (1 May 2010 version). Copy number polymorphisms (CNPs) identified in these 261 early/mixed-onset families based on 470% overlap with CNPs in DGV (last update November 2010) were excluded from further analysis. [26] [27] [28] [29] The latest version of DGV lists close to 67K CNVs in about 16K genomic loci. using two methods: (a) utilizing a novel algorithm that we developed for this study to perform CNV segregation analysis (genomic segment correlator, GSC) and (b) visual analysis for segregation using the UCSC genome browser. The physical start and end positions of the CNVs, phenotype and pedigree information of each sample were supplied as input to GSC (Supplementary Figure 3) . CNVs with 450% overlap in genomic region were treated as a single event because of the ambiguity of CNV end points in calls inferred from micro-array intensity data. Each family was separately analyzed for CNVs that co-segregated with the disease status. Genetic heterogeneity was accounted for by excluding late-onset AD patients (onset 465 years of age) from segregation analysis within pedigrees. Only those CNV segments that were present in affected members of the test family, and absent in 'controls' were subjected to further analysis. The 'control' samples are unaffected subjects from the entire set of early/mixed-onset families, as well as, the remaining late-onset AD families-a total of 1222 unaffected subjects. Following visual confirmation on UCSC Genome Browser using custom tracks in BED format, 30 CNVs showing inheritance patterns consistent with disease causation were prioritized for CNV confirmation. See supplementary for more details on GSC.
For visual analysis in the UCSC Genome Browser method, custom tracks were created comprising all the PennCNV segments, and were integrated into the browser. A window spanning a 2-Mb genomic interval was visually analyzed for CNVs segregating with disease-and in a sliding window manner we then covered all autosomes. Rare CNVs showing pathogenic inheritance in the early/mixed-onset AD families were compared against CNVs detected in the rest of the NIMH and NCRAD late-onset families (n ¼ 506) consisting of 1547 subjects. Only rare CNVs that co-segregated with AD exclusively in affected subjects in the early/mixed-onset families were included in further analysis.
CNV validation
CNVs that co-segregated with AD were validated using Fluidigm Digital 48.776 arrays (Fluidigm Corporation, San Francisco, CA, USA) and TaqMan copy number probes. 31 Depending on the availability of tissue samples, several CNVs were also confirmed using fluorescence in-situ hybridization as described previously 32 using Epstein-Barr virus-transformed lymphoblast cell lines derived from the subjects.
RESULTS
PennCNV was utilized to make CNV calls in all 261 early/mixedonset AD families. The total number of CNVs detected, CNV burden (average CNVs per individual), average CNV segment size, copy number (CN) gains and CN losses detected per sample are listed in Table 1 . The overall frequency of CNVs identified in nearly 1000 subjects from 261 early/mixed-onset AD families (Table 1 ) are similar to that described in previous studies utilizing the Affymetrix SNP 6.0 microarray. 23, 33 CNV segments that showed o70% overlap with CNPs reported on DGV were analyzed for segregation with disease. These analyses confirmed APP locus duplication previously reported in two EO-FAD families. 34 In addition to these, we observed 10 (NIMH sample) and 7 (NCRAD families) novel CNVs, which co-segregated with disease exclusively in EO-FAD families. These 17 CNVs were absent from all other NIMH and NCRAD AD families (total of 2796 samples from 825 families), were not found in any unaffected subjects, and did not overlap with published CNVs or CNPs in DGV-suggesting that they are AD specific. Subsequent CNV confirmation assays validated 10 of the 17 CNVs (Table 2) ; the majority of false-positive CNVs (five out of seven) involved genomic duplications. All the 10 validated CNVs were novel and private in the early/mixed-onset AD families. Five of the 10 novel CNVs identified (Table 2) were heterozygous deletions for which the average familial onset age was 60.5 years, and the average CNV size was 224 kb. These CNVs overlapped with the genes: CHMP2B, POU1F1, KANK1, DMRT1, DMRT3, FLJ35024, VLDLR and A2BP1. Five of the 10 novel CNVs identified were CN gains (Table 2) for which the average familial onset age was 58.75 years, and the average CNV size was 501 kb. These CNVs overlapped with the genes: MAPT, CDH2, ERMP1, EVC, EVC2, CRMP1 and EPHA6. For 6 of the 10 CNVs, the APOE-e4 allele also co-segregated with AD, suggesting that the genes affected by the CNVs and the APOE-e4 allele combine as genetic modifiers for AD risk. Note that two CNVs were found to encompass known frontotemporal lobar dementia genes, that is, CHMP2B and MAPT (Table 2) .
Finally, we set out to confirm that the 10 EO-FAD families co-segregating the novel CNVs with AD do not contain mutations in genes that have been previously implicated in EO-FAD and frontotemporal lobar dementia. 35 To this end, we re-sequenced APP, PSEN1, PSEN2, MAPT and GRN for pathogenic mutations in probands from the entire collection of NIMH and NCRAD families, including the 261 early/mixed-onset families (Supplementary Table 1 ). No pathogenic sequence variants were detected in the 10 EO-FAD families that co-segregated with novel private CNVs with AD. However, 11 pathogenic sequence variants were identified in other families, along with a novel mutation (M84V) in PSEN1. Similar to a previous finding, 36 the known pathogenic PSEN1 EO-FAD mutation, A79V, was found to co-segregate with AD in a late-onset AD family (average onset age ¼ 74.5 years).
DISCUSSION
The primary goal of this study was to identify novel CNVs that co-segregate with EO-FAD in families for which mutations in APP, PSEN1 and PSEN2 have been ruled out. To date, the only established CNV in AD is the duplication of the APP gene. 34 Considering the exceedingly rare frequency of the APP CNV in EO-FAD, we searched for other rare and novel CNVs co-segregating with AD in EO-FAD kindreds. For this purpose, we developed and used a novel algorithm GSC (Supplementary Figure 3) . Using the GSC, we identified 10 novel and private CNVs in 10 EO-FAD families. The potential pathogenicity of these 10 novel CNVs is supported by the nature of these mutations-all deletions or duplications within various genes, observed specifically in EO-FAD patients with age of onset o65 years. The potential causality of these novel and rare CNVs for EO-FAD is further supported by their Overall summary of CNVs identified from microarray probe intensity data in EO-FAD and early/mixed-onset Alzheimer's family samples. The average values per subject are indicated in the parenthesis. The number and fraction of subjects positive for the e4 risk allele are listed in the column APOE-e4 positive.
Rare autosomal CNVs in EO-FAD BV Hooli et al tight co-segregation with AD in these 10 families. All but one (FAD-CNV7) of the 10 CNVs are exclusively observed in affected subjects in these families, whereas absent in the rest of the affected and unaffected individuals in our AD families (N ¼ 561 families; N ¼ 1750 subjects). In addition, all 10 CNVs are absent in the publicly available CNV database on the DGV. 
Rare autosomal CNVs in EO-FAD BV Hooli et al
Evidence for possible genetic heterogeneity was observed in three of the families. In one family, NH1, FAD-CNV7 was observed in a single unaffected subject (NH1-II.94) for whom the last diagnosis was made in 2006 with no information on current age or latest disease status. In another family, NH4, one subject (NH4-II.80) was listed as 'probable dementia' but did not carry FAD-CNV10, a duplication of MAPT. It should be noted, however, that family NH4 likely involves genetic heterogeneity (similar to that observed in the control family ND7-APP duplication). FAD-CNV10 co-segregates with AD in all three early-onset patients (onset o62 years), but not in the sole late-onset family member (onset ¼ 71 years). Finally, family ND5 may also represent a case of genetic heterogeneity since one subject (ND5-II.73) did not carry FAD-CNV5 while two EO-FAD patients with onset o65 years did carry. The non-carrier is listed as 'possible dementia' with no onset age available; unfortunately, no other information is available on this subject. Collectively, our findings support the probable pathogenicity of these CNVs as novel forms of genomic mutation leading to EO-FAD.
The 10 CNVs identified in this study affect genes implicated in a variety of neuronal function pathways and some have been previously been implicated in other neurodegenerative disorders. FAD-CNV1 was detected in two affected siblings (onset ages: 40 and 42 years, both APOE-e4 negative), with no unaffected siblings, from family ND1. This 124-kb CN loss segment, overlaps CIP150 (KIAA1432) and ERMP1. CIP150 has been reported to be essential for phosphorylation and localization of Cx43, 37 one of the most ubiquitous gap junction protein. Gap junction proteins are specialized in intercellular connection between various cell types, notably at the synapses and is associated with both neuroprotective 38 and neurodestructive 39 functions. ERMP1 has not been characterized in great detail, but encodes a zinc-dependent endoplasmic reticulum metallopeptidase, with decreased expression in a transgenic AD mouse model; 40 higher ERMP1 expression has been reported in epilepsy mouse models. 41 Two affected siblings from family ND2 (onset ages: 52 and 56, APOE-e4 negative) with no unaffected siblings, carry FAD-CNV2 (240-kb gain), which overlaps EVC, EVC2 and CRMP1. Mutations in EVC and EVC2 cause the bone growth disorder (dwarfism), EllisVan Creveld syndrome (OMIM: 225500) and the skeletal disorder, Weyers acrofacial dysostosis (OMIM: 193530), however, gene function is unknown.
42 CRMP1 belongs to cytosolic phosphoprotein family and is highly expressed in the brain. 43 CRMP1 has a role in SEMA3A-(a gene associated with AD 44 ) mediated regulation of neural growth and axonal guidance, and microtubule assembly. 43, [45] [46] [47] Considering the role of CRMPs in axonal guidance and regeneration in the brain, gain in CRMP1 could compromise neuroplasticity with aging and thus lead to AD. Interestingly, CRMP2 has been reported to be hyper-phosphorylated as an early event in AD pathogenesis. 48 FAD-CNV3 (110 kb, CN loss) was observed in two affected siblings (onset age: 56 and 68, APOE-e4 negative) with no unaffected siblings. The closest genes in the proximity are A2BP1 located 0.3-Mb telomeric, and ABAT, which is 0.57-Mb centromeric to the CNV breakpoint. Studies suggest CNVs can alter expression levels of genes more than to 2 Mb away; 16, 49 thus, both genes could possibly undergo CNV-mediated dysregulation. A2BP1 controls splice variants in many genes-mainly neurodevelopmental, and loss in gene function is associated with various conditions, including: mental retardation, epilepsy, autism spectrum disorder and obesity.
9,50-52 ABAT is involved in catalyzing neurotransmitter GABA (gamma-aminobutyric acid), and associated with various neuronal disorders. 53, 54 Two of three affected siblings (onset ages 64 and 65, APOE-e4 positive) carry FAD-CNV5, while the third affected sibling (unknown onset age) did not. The 488-kb gain in CN encompasses CDH2, encoding N-cadherin, which is expressed in brain, skeletal and cardiac muscles and has critical roles in synaptic adhesion, dendritic morphology and neuritic growth. [55] [56] [57] [58] [59] CDH2 has been extensively studied in AD. For example, inhibition of N-cadherin function has been reported to accelerate Ab-triggered synapse damage. 60 Moreover, dissociation of N-cadherin-mediated synaptic contact by Ab has been proposed to cause neuronal cell death, synaptic loss and tau phosphorylation in AD brain. 61 Two affected siblings in family ND6 show the presence of FAD-CNV6, a 0.73-Mb intergenic gain in CN. EPHA6 is located 0.33-Mb telomeric and the only described gene in close proximity. EPHA6 is highly expressed in brain and involved in forming neural networks, 62 and has been shown to cause learning and memory impairment in knock-out mice, 63 suggesting that EPHA6 dysregulation as a possible pathogenic pathway leading to AD. The 400-kb deletion (FAD-CNV7) shows partial overlap (59%) with CNPs in DGV, and overlaps KANK1, DMRT1 and DMRT3. Locus 9p24.3 has been reported in numerous disorders including, chromosome 9p deletion syndrome 64 (OMIM: 158170), cerebral palsy (OMIM: 607704), obsessive compulsive disorder 65 suggesting a role for these loci with neuronal function and various disorders.
Two affected siblings in family NH2, onset age 45 and 61, contain a 331-kb deletion (FAD-CNV8) overlapping CHMP2B and POU1F1, while two unaffected siblings were negative for the CNV. Both affected individuals are homozygous for the APOE-e4 allele, while the two unaffected siblings were heterozygous for APOE-e4 allele with current ages of 75 and 83. CHMP2B has been previously shown to harbor rare pathogenic mutations leading to frontotemporal dementia (OMIM: 609512) and amyotrophic lateral sclerosis (ALS, OMIM: 600795). CHMP2B is expressed in all neuronal populations and colocalizes with granulovacuolar degenerationone of the pathological hallmarks in AD. 66, 67 The partially deleted adjacent gene, POU1F1 (OMIM: 173110), has been reported to cause pituitary hormone deficiency and is associated with mental retardation. 68, 69 CHMP2B has also been implicated in endosomal trafficking, the disruption of which could lead to neurodegeneration. 70 FAD-CNV9, a 151-kb CN loss, was detected in two affected subjects (AAO: 62, 75 and APOE-e4 positive) in family NH3 overlapping FLJ35024 and VLDLR. VLDLR has been previously studied as a candidate gene in AD, albeit without evidence for strong association (www.alzgene.org). 71 VLDLR has been reported to be involved in multiple AD-related pathways, including acting as a receptor for APOE as well as roles in Tau phosphorylation and synaptic functioning via interaction with RELN. 72, 73 Numerous pathogenic mutations in VLDLR have also been reported to cause cerebral ataxia and mental retardation (OMIM: 224050).
Finally, we also observed three affected siblings in family NH4 to carry a 170-kb duplication spanning MAPT (FAD-CNV10). MAPT encodes the microtubule-associated Tau protein, which in its hyper-phosphorylated and paired helical filament state creates neurofibrillary tangles in AD and tauopathies. 1 Tau is ubiquitous in neuronal axons and crucial to microtubule assembly. Pathogenic mutations in MAPT, including CNVs, have been previously implicated in frontotemporal dementia and 17q21.31 microduplication with variable phenotype. 74 Rovelet-Lecrux et al. 75 previously described a 439-kb microduplication at the 17q21.31 locus encompassing the MAPT, IMP5, CRHR1 and STH genes in the proband of a family in which three patients displayed an frontotemporal lobar dementia phenotype. In our study, only MAPT was duplicated in all three affected siblings. Thus, this is the first evidence for duplication of solely MAPT leading to a dementia phenotype. It remains to be determined (pending autopsy confirmation) whether family NH4 is affected with AD, frontotemporal lobar dementia or a disorder that encompasses both forms of these dementias.
In summary, we have systematically analyzed EO-FAD and early/ mixed-onset AD families for CNVs putatively conferring pathogenicity. We have identified a dozen rare, novel and large CNV regions that co-segregate with disease status within families. The genes implicated by these CNVs have roles in wide range of neuronal pathways critical to normal functioning of the brain. Further studies will be required to elucidate the precise pathogenic mechanisms underlying the co-segregation of these CNVs with AD in our family data sets.
Supplemental data description Supplementary Table 1 shows the results of our screening for known mutations in APP, PSEN1, PSEN2, MAPT and GRN. The table lists the pathogenic mutations identified in early-onset AD pedigrees in the three known genes in AD and frontotemporal dementia.
Supplementary Figure 1 shows the fluorescent in-situ hybridization (FISH) images of lymphoblastoid cell lines derived from probands and the corresponding DCt values from Fluidigm CNV assay. Supplementary Figure 2 shows the pedigree structure of the families found to carry CNVs that show pathogenic form of inheritance.
